| (1) | A list of the financial statements filed as part of this Annual Report on Form 10-K is set forth in the index to consolidated financial statements on Page 30 and is incorporated herein by reference. |
(2) An index of exhibits incorporated by reference or filed with this Annual Report on Form 10-K is provided below.
| Number | Description |
| 3.1 | Certificate of Incorporation of Integrated BioPharma, Inc., as amended (6) |
| 3.2 | Certificate of Amendment to the Restated Certificate of Incorporation of Integrated BioPharma, Inc. (6) |
| 3.3 | By-Laws of Registrant (4) |
| 4.1 | Certificate of Designation of Series and Determination of Rights and Preferences of Series A Convertible Preferred Stock of Integrated BioPharma, Inc. dated June 25, 2003 (1) |
| 4.2 | Certificate of Designation of Series C and Determination of Rights and Preferences of Series C Convertible Preferred Stock of Integrated BioPharma, Inc. dated February 21, 2008 (5) |
| 10.1 | Lease Agreement between the Company and Vitamin Realty Associates, dated January 10, 1997 (2) |
| 10.1.1 | Second Amendment of Lease, dated as of January 5, 2012, between Vitamin Realty Associates, L.L.C. and InB:Manhattan Drug Company, Inc. (8) |
| 10.1.2 | Third Amendment of Lease, dated as of July 15, 2022, between Vitamin Realty Associates, L.L.C. and Manhattan Drug Company, Inc. (9) |
| 10.1.3 | Fourth Amendment of Lease, dated as of February 17, 2026, between Vitamin Realty Associates, L.L.C. and Manhattan Drug Company, Inc. (13) |
-27-
| 10.2 | Integrated Health Technologies, Inc. 2001 Stock Option Plan, as amended (7) |
| 10.3 | Lease Agreement between Elizabeth Industrial Park, LLC c/o Palin Enterprises, and MDC Warehousing and Distribution, Inc. dated November 22, 2022. (10) |
| 10.4 | Loan Agreement dated as of April 15, 2025 between Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association (11) |
| 10.4.1 | Amendment to Loan Document dated as of April 15, 2025 by and between Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association (14) |
| 10.5 | Promissory Note - Line of Credit dated April 15, 2025 by and among Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association (11) |
| 10.6 | Promissory Note - Convertible Line of Credit dated April 15, 2025 by and among Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association (11) |
| 10.6.1 | Cancellation of Promissory Note –Convertible Line of Credit dated April 15, 2025 by and among Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association (14) |
| 10.7 | Security Agreement dated as of April 15, 2025 by and between Integrated BioPharma, Inc. and PNC Bank, National Association (11) |
| 10.8 | Security Agreement dated as of April 15, 2025 by and between Manhattan Drug Company, Inc. and PNC Bank, National Association (11) |
| 10.9 | Reimbursement Agreement for Standby and Commercial Letter(s) of Credit dated as of April 15, 2025 by and among Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and PNC Bank, National Association and any Bank Affiliate (11) |
| 10.10 | Convertible Line of Credit Note (Daily SOFR) dated June 30, 2026 by Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. and payable to the order of PNC Bank, National Association (14) |
| 14 | Code of Business Ethics (3) |
| 19 | Insider Trading Policy (12) |
| 21 | Subsidiaries of the Registrant (15) |
| 23 | Consent of Independent Registered Public Accounting Firm (15) |
| 31.1 | Certification of Periodic Report by Chief Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (15) |
| 31.2 | Certification of Periodic Report by Chief Financial Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (15) |
| 32.1 | Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (15) |
| 32.2 | Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (15) |
| 101 | The following financial information from Integrated BioPharma, Inc.’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026, formatted in XBRL (extensible Business Reporting Language): (i) Consolidated Statements of Income for the fiscal years ended June 30, 2026 and 2025, (ii) Consolidated Balance Sheets as of June 30, 2026 and 2025, (iii) Consolidated Statements of Changes in Stockholders’ Equity for the fiscal years ended June 30, 2026 and 2025 , (iv) Consolidated Statements of Cash Flows for the fiscal years ended June 30, 2026 and 2025, and (v) the Notes to Consolidated Statements. (15) |
| 104 | Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101) |
| (1) | Incorporated herein by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003, filed with the SEC on September 29, 2003. |
| (2) | Incorporated herein by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 1997, filed with the SEC on September 29, 1997. |
| (3) | Incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 12, 2022. |
| (4) | Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on February 14, 2008. |
-28-
| (5) | Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on February 22, 2008. |
| (6) | Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on May 12, 2008 and to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003 filed with the SEC on September 29, 2003. |
| (7) | Incorporated herein by reference to the Company's Definitive Proxy Statement on Form DEF 14A, as revised, filed with the SEC on October 28, 2009. |
| (8) | Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 filed with the SEC on May 21, 2012. |
| (9) | Incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 filed with the SEC on September 13, 2022. |
| (10) | Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 filed with the SEC on February 10, 2023. |
| (11) | Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on April 21, 2025. |
| (12) | Incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025 filed with the SEC on September 23, 2025. |
| (13) | Incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on February 18, 2026. |
| (14) | Incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 2, 2026. |
| (15) | Filed herewith. |
